Effect of Human Mesenchymal Stem Cells (Remestemcel-L) on Clinical Response and Survival Confirmed in a Large Cohort of Pediatric Patients with Severe High-Risk Steroid-Refractory Acute Graft Versus Host Disease
Joanne Kurtzberg(Duke University), Donna Skerrett(Mesoblast (United States)), Eneida R. Nemecek(Oregon Health & Science University), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Jack Hayes(Mesoblast (United States)), Sonali Chaudhury(Northwestern University), Biljana Horn(UF Health Shands Hospital), Vinod K. Prasad(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Elizabeth Burke(Mesoblast (United States)), Pierre Teira(Université de Montréal)
Cited by 3
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369